A phase 1 clinical trial of the sigma-2 receptor complex allosteric antagonist CT1812, a novel therapeutic candidate for Alzheimer's disease.

Name: A phase 1 clinical trial of the sigma-2 receptor complex allosteric antagonist CT1812, a novel therapeutic candidate for Alzheimer's disease.
Author: Grundman, Michael

A phase 1 clinical trial of the sigma-2 receptor complex allosteric antagonist CT1812, a novel therapeutic candidate for Alzheimer's disease. — المؤلف: Grundman, Michael — Alzheimer's & dementia (New York, N. Y.) 2019

المؤلف: Grundman, Michael
النشر: Alzheimer's & dementia (New York, N. Y.) 2019
الوصف: 20-26 p.